1.0505  0.113 (11.99%)		01-09 13:11
Open: 0.93 High: 1.07 Volume: 308,972		Pre. Close: 0.938 Low: 0.93 Market Cap: 26(M)

Short term
Mid term
Targets	6-month :	1.44	1-year :	1.69
Resists	First :	1.24	Second :	1.44
Pivot price	0.83
Supports	First :	0.89	Second :	0.68
MAs	MA(5) :	0.91	MA(20) :	0.84
	MA(100) :	1.08	MA(250) :	1.26
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	86.9	D(3) :	80
RSI	RSI(14): 61.4
52-week	High :	2.59	Low :	0.68

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NRSN ] has closed Bollinger Bands are 8.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.94 - 0.94	0.94 - 0.95
Low:	0.84 - 0.84	0.84 - 0.85
Close:	0.93 - 0.94	0.94 - 0.95

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Fri, 09 Jan 2026
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm

Tue, 06 Jan 2026
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks

Mon, 22 Dec 2025
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Thu, 04 Dec 2025
NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan

Wed, 10 Sep 2025
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons - PR Newswire

Thu, 04 Sep 2025
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	30 (M)
Shares Float	14 (M)
Held by Insiders	21.5 (%)
Held by Institutions	0.9 (%)
Shares Short	681 (K)
Shares Short P.Month	243 (K)

EPS	-0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.02
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-303.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.29
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-2.91
PEG Ratio	0
Price to Book value	-52.25
Price to Sales	0
Price to Cash Flow	-3.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.